Repository logo
 

Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series

Published version
Peer-reviewed

Type

Article

Change log

Authors

Murphy, HR 
Kumareswaran, K 
Elleri, D 
Allen, JM 
Caldwell, K 

Abstract

OBJECTIVE: To evaluate the safety and efficacy of closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII). RESEARCH DESIGN AND METHODS: A total of 12 women with type 1 diabetes (aged 32.9 years, diabetes duration 17.6 years, BMI 27.1 kg/m(2), and HbA(1c) 6.4%) were randomly allocated to closed-loop or conventional CSII. They performed normal daily activities (standardized meals, snacks, and exercise) for 24 h on two occasions at 19 and 23 weeks' gestation. Plasma glucose time in target (63-140 mg/dL) and time spent hypoglycemic were calculated. RESULTS: Plasma glucose time in target was comparable for closed-loop and conventional CSII (median [interquartile range]: 81 [59-87] vs. 81% [54-90]; P = 0.75). Less time was spent hypoglycemic (<45 mg/dL [0.0 vs. 0.3%]; P = 0.04), with a lower low blood glucose index (2.4 [0.9-3.5] vs. 3.3 [1.9-5.1]; P = 0.03), during closed-loop insulin delivery. CONCLUSIONS: Closed-loop insulin delivery was as effective as conventional CSII, with less time spent in extreme hypoglycemia.

Description

Keywords

Adult, Blood Glucose, Cross-Over Studies, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Pregnancy, Pregnancy in Diabetics

Journal Title

Diabetes Care

Conference Name

Journal ISSN

0149-5992
1935-5548

Volume Title

34

Publisher

American Diabetes Association
Sponsorship
Diabetes UK (None)
TCC (None)
Medical Research Council (G0600717)
Medical Research Council (G0600717/1)
This work was funded by a Diabetes UK project grant (BDA 07/003551). H.R.M. was funded by a National Institute for Health Research (NIHR) research fellowship (PDF/08/01/036). The research was conducted with support from the Juvenile Diabetes Research Foundation, Abbott Diabetes Care (FreeStyle Navigator continuous glucose monitors and sensors), the investigator-initiated study program of the Animas Corporation (Animas 2020 insulin pump), the Medical Research Council Center for Obesity and Related Metabolic Diseases, the NIHR Cambridge Biomedical Research Center, and Addenbrooke's Clinical Research Facility (Cambridge, U.K.). No funder had any role in the study design; data collection, analysis, and interpretation; or manuscript preparation.